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The aim of this study was to evaluate the efficacy
of meso-2,3-dimercaptosuccinic acid (DMSA)
treatment in workers with increased lead
absorption and no overt symptoms of lead
poisoning. Seven occupationally lead exposed
male workers with blood lead concentrations
(PbB) exceeding 50 µg/100 ml and a positive
calcium disodium ethylenediaminetetraacetate
(EDTA) lead mobilization test were treated with
DMSA for 19 days. Individual doses were 700 mg
DMSA, three times a day from day one to five,
and twice a day from day six to 19. The treatment
intensified urinary lead excretion, most rapidly
during the first five days. The increased
elimination was followed by a decline of mean
PbB to 15% of the pretreatment values. However,
15 days after the treatment, the PbB concentra-
tions rebounded, yet kept below the baseline
values and did not exceed 40 µg/100 ml. After
repeated EDTA lead mobilization test, urine lead
was 23–68% of that before DMSA treatment. It
can be concluded that DMSA can effectively
reduce chelatable lead in occupationally exposed
workers.
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Chelating agents such as calcium disodium ethylenediaminetetraacetate (CaNa2EDTA),
2,3-dimercapto-1-propanol (BAL), and d-penicillamine have been widely used in the
treatment of acute and chronic lead poisoning. In more than 40 years of use, exten-
sive experience has defined their advantages as well as the disadvantages and side
effects (1–3). Meso-2,3-dimercaptosuccinic acid (DMSA) has been used in China as
a chelator in lead poisoning since 1965 (4). In the USA, it was first tested in late 70s
(5) and its efficacy and safety were soon confirmed (6, 7). Today, DMSA is considered
the most promising new oral chelating drug, whose effectiveness in metal mobilization
is particularly evident in the therapy of lead poisoning in children (8, 9). In Croatia,
however, DMSA has not yet been applied as a drug, either in children or in adults.
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There are only a few reports on DMSA chelation in occupationally exposed workers (10,
11). The therapeutic benefit of chelation in chronic lead poisoning, especially in cases
with fewer overt subclinical forms of lead toxicity, is still a subject of discussion (12).
The aim of this study was to evaluate the efficacy of DMSA treatment in occu-
pationally lead exposed workers with increased chelatable lead and without overt clin-
ical symptoms of lead intoxication.
SUBJECTS AND METHODS
The study included seven lead exposed male workers employed in manufacture of
lead batteries. Two workers aged 25 and 27 had been exposed to lead for four years,
other two aged 35 and 36 for 10 years, and three workers aged 38, 51, and 45 for
11, 12, and 23 years, respectively. Patients were socioeconomically comparable and
had had similar personal habits including alcohol intake. The following criteria were
used for the inclusion in the study: a) occupational lead exposure, b) blood lead levels
(PbB) exceeding 50 µg/100ml (2.41 µmol/L) determined in a periodic examination
that had taken place approximately one month before the study, and c) positive
EDTA lead mobilization test.
Having given informed consent, the subjects were hospitalized for the entire
study, which secured cessation of exposure and appropriate observation. All proce-
dures were carried out according to the ethical standards approved by the Ethic
Committee of the Institute for Medical Research and Occupational Health. The entire
therapeutic protocol was approved by the Croatian Drug Committee.
The EDTA lead mobilization test was done by measuring 24-hour lead excretion
in urine (PbU) after administration of 1 g CaNa2EDTA (LEDCLAIR ampules, Sinclair,
UK) in 250 ml of 5% glucose i.v. over one hour. An EDTA test was considered
positive if PbU excretion exceeded 600 µg/24 hrs (13, 14), which was consistent with
the increase in chelatable lead (15).
The treatment began six days after the EDTA test. Capsules of DMSA (CHEMET,
McNeil, USA) were donated by a co-manufacturer Cilag, Switzerland. The treatment
protocol and the inclusion criteria for the study (PbB 50 µg/100 ml) followed the
manufacturer’s instructions. Oral DMSA treatment consisted of 700 mg administered
three times a day from days 1–5, and twice a day from days 6–19.
Five ml of blood from cubital vein was collected for PbB analysis. Electrothermal
atomic absorption spectrometry (ET-AAS) was applied after deproteinization with ni-
tric acid according to a modified Stoeppler method (16, 17). Measurements were
performed on Perkin Elmer, Model 5100 with Zeeman background correction. The
method has constantly been verified by participation in the United Kingdom National
External Quality Assessment Scheme programme (coefficient of variation, CV<1%).
Initial PbB concentrations were determined before the EDTA test. During DMSA
treatment, PbB was measured on day 5, 12, and 19 and again 15 days after the
treatment. Simultaneous laboratory tests included blood count and renal and liver
function tests, i.e. concentrations of electrolytes, uric acid, serum creatinine, serum
transaminases, bilirubin, alkaline phosphatase, and creatinine clearance.
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A baseline 24-hour urine lead was obtained before the EDTA test (PbU0). The
24-hour urine samples for urine lead were collected repeatedly during the first five
days, and then again on day 12 and day 19 of DMSA treatment. Urine lead concen-
trations were determined by ET-AAS (Perkin-Elmer, 5100; CV<5%) (18).
Other elements, that is, zinc (Zn), copper (Cu), iron (Fe), calcium (Ca), and mag-
nesium (Mg) excretion in urine were analyzed in samples collected on days 0, 5, and 19.
Ten ml of urine was dried, ashed at 450 0C in quartz crucibles, and dissolved in 10 ml
of 2% HNO3. The analyses were carried out by flame atomic absorption spectrometry on
a Varian, Model AA375, with deuterium background correction (CV<5%) (19).
The EDTA lead mobilization test was repeated 15 days after the DMSA treatment
to evaluate the efficacy of DMSA in reducing lead accumulation.
Since the employers’ policy required workers to return to work immediately after
normalization of PbB (<40 µg/dl), the follow-up did not extend over the 15 days after
the cessation of the treatment.
The statistical difference between the results of EDTA lead tests and PbB con-
centrations obtained before and after the treatment was analyzed by Student’s t-test
for dependent samples using the CSS Biostatistica program (Statsoft 1991 package,
release 3.1).
RESULTS
The EDTA lead mobilization test showed urinary lead excretion reaching up to 150%
above the threshold level of 600 µg/24 h (range 953–1634 µg Pb/24 h), which was
consistent with an increase of chelatable lead of PbB≥40 µg/dl in the seven workers
(Table 1).
Table 1 Urinary lead excretion (µg Pb/24 h) after each EDTA mobilization test*
EDTA lead mobilization test
Patient Before DMSA After DMSA Reduction (%)
1 1120 630 44
2  953 – –
3 1345 629 53
4 1395 770 45
5 1634 379 77
6 1014 689 32
7 1041 256 75
Mean ± SD 1214 ± 243 559 ±198† 54 ± 18
* The first EDTA lead mobilization test was done six days before the start,
and the second 15 days after the end of DMSA treatment by intravenous
infusion of one gram CaNa2EDTA in 250 ml 5% glucose solution,
administered during one hour (referent values <600 µg Pb/24 h urine).
† Statistically different from values before treatment at P<0.01
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The DMSA treatment significantly increased urine lead, especially on days 1–5
(Table 2). Six workers manifested a decline in urine lead after EDTA to 54±18% of
pretreatment PbU (P<0.01) (Table 1).
Table 2 Urinary lead (PbU) excretion (µg/24 h) before and during the treatment with DMSA*
in workers occupationally exposed to lead.
Days of DMSA treatment
Patient PbU0 1. 2. 3. 4. 5. 12. 19.
1 98 1570 1369 1156  916 924 306 329
2 83 1142  931  545  631 642 241 154
3 75 1333  967  841  577 616 277 137
4 66 1204  952  890  596 692 322 199
5 66 2058 1416  913  723 661 283 177
6 57 1597 1663 1113 1230 740 458 294
7 57  588 1040  949  836 850 487 218
* DMSA treatment lasted 19 days, with individual doses of 700 mg three times a day
from days 1–5, and twice a day from days 6–19. A baseline 24–hour urine lead (PbU0)
was obtained six days before the start of DMSA treatment and before the first EDTA
lead mobilization test.
Mean PbB (Table 3) significantly dropped (P<0.01) to 25% of the baseline con-
centrations determined before the EDTA test. Fifteen days after the cessation of
treatment (i.e. on day 34) PbB values were down to 51% of the initial value (P<0.01)
Table 3 Lead in blood (µg Pb/dl) before, during, and after treatment with DMSA
Treatmenta
Patient Before During After Post-treatment Rebound
Day 5 Day 12 Day 19
reduction (%)b (%)c
1 41.4 13.2 10.1 8.9 24.2 78.5 36.9
2 39.5 12.2 7.66 4.76 – 88.0 –
3 43.5 11.8 8.69 5.38 18.8 87.6 30.9
4 45.5 12.4 9.32 6.67 25.9 85.5 42.2
5 54.9 14.3 9.73 7.87 19.9 85.7 21.9
6 59.0 14.9 11.2 10.6 30.4 82.0 33.6
7 33.3 7.25 4.55 4.97 19.2 85.1 42.7
Mean ± SD 45.3 ± 8.9 12.3 ±2.5 8.75 ± 2.15 7.02 ± 2.20† 23.1 ± 4.6†‡ 84.6 ± 3.3 34.7 ± 7.8
a DMSA treatment lasted 19 days, with individual doses of 700 mg three times a day from days 1–5, and twice a day from
days 6–19. The first PbB was analyzed six days before the start, and the last 15 days after the end of DMSA treatment.
b Post-treatment reduction (at day 19) was calculated as percent reduction of PbB value obtained before the treatment.
c Rebound was calculated as per cent of: PbBAfter - PbBDay 19 / PbBBefore
† Statistically different from before treatment and from Day 19 at P<0.01, respectively.
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and did not exceed the threshold level for the occupationally exposed workers of 40
µg/100 ml (20).
In contrast to the early excretion of lead, the urinary excretion of trace elements
increased with the duration of DMSA treatment (Figures 1 and 2).
Figure 1 Zinc (Zn), copper (Cu), and iron (Fe) in 24-hour urine before (day 0), during (day 5) and after
(day 19) DMSA treatment
Figure 2 Calcium (Ca) and magnesium (Mg) in 24-hour urine before (day 0), during (day 5) and after
(day 19) DMSA treatment
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There were no clinically significant changes in the blood count. Clinical chemistry
changes were limited to a mild and transient rise in alanine transaminase in three of
the seven subjects.
DISCUSSION
This study of DMSA chelation in seven workers occupationally exposed to lead for several
years with increased chelatable lead on EDTA lead mobilization test was prompted by the
emerging evidence that toxic effects of lead exposure may occur at PbB≤40 µg/dl (21).
The PbB declined rapidly in the first five days of DMSA treatment. On day 19,
the PbB concentrations dropped to approximately 15% of the pretreatment values.
Like in other studies (10, 11), the decline in PbB was associated with increased PbU.
Experimental investigations show that DMSA reduces lead concentrations in blood,
brain, kidney, and liver, even in the face of continued Pb exposure (22, 23). A major
question is whether DMSA mobilizes skeletal lead and redistributes it to target organs,
especially the brain. Cory-Slechta (24) reported that DMSA did not produce any
observable depletion in the bone lead concentration. There was a dose-related in-
crease in bone lead and it was proposed that chelation therapy redistributed lead
from the soft tissue compartments to the bone. Similar results were described by
Smith and Flegal (25). However, some authors showed a significant decrease of
bone lead due to DMSA chelation (23, 26). Blanu{a and co-workers (26) treated
suckling rats with DMSA and a monoisoamyl ester of DMSA after loading them with
lead and found that both chelators caused a significant decrease of lead concentra-
tion in the brain.
Consistently with previous human and animal studies (10, 27), we found a two-
fold to threefold increase in the excretion of zinc and copper during DMSA treatment,
along with slight variations in the excretion of iron, calcium, and magnesium.
The rebound of PbB after cessation of DMSA treatment was similar to that in
other studies (10, 28) and was attributed to re-equilibration of lead from bone stores
into the blood (29). A significant post-chelation rebound may indicate a preponder-
ance of lead in slow pools and a small impact of chronic, heavy exposure on the total
body stores. However, Grandjean and co-workers (11) treated a chronically lead
poisoned patient with neurologic symptoms (headache, fatigue, vertigo, decreased
memory and concentration) with five courses of DMSA treatment. Despite a rebound
of blood lead after each treatment course, a significant improvement in patient’s
mental status occurred at the end of treatment. The clinical significance of redistribu-
tion and rebounding of lead remains unclear.
The justifiable use of chelation in occupationally lead exposed workers is contro-
versial. The recommended therapy for industrial lead intoxication is to cease exposure
until blood lead decreases to 1.95 µmol/L (40.4 µg/100 ml). Chelation therapy should
be reserved for those with significant symptoms or signs of toxic reactions (30).
However, there are serious gaps in the knowledge of the chronic, subclinical toxicity
of lead and dose-response relationships are still largely uncertain (31, 32) as is the
role of chelation therapy.
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Sa‘etak
PRIMJENA mezo-2,3-DIMERKAPTOJANTARNE KISELINE U RADNIKA
PROFESIONALNO IZLO@ENIH OLOVU
Svrha ovog istra‘ivanja bila je ustanoviti u~inkovitost  mezo-2,3-dimerkaptojantarne kiseline (DMSA) u radnika s
pove}anom apsorpcijom olova, a bez znakova trovanja olovom. Danas se DMSA smatra jednim od najboljih
kelatiraju}ih sredstava, koje se pokazalo u~inkovitim posebno u djece otrovane olovom. U Hrvatskoj, me|utim, do
sada jo{ nije bilo primjenjivano.
Sedam radnika profesionalno izlo‘enih olovu bilo je tretirano s DMSA. Radnici nisu imali klini~kih simptoma
otrovanja olovom, koncentracija olova u krvi bila je vi{a od 50 µg/100 ml, a mobilizacijski test s  kalcij dinatrij
etilendiamintetraacetatom (EDTA) bio je pozitivan. Postupak je trajao 19 dana davanjem pojedina~nih doza od 700
mg DMSA tri puta na dan od prvog do petog dana i dva puta na dan od {estog do devetnaestog dana.
Rezultati su pokazali da je izlu~ivanje olova urinom za vrijeme primjene DMSA bilo povi{eno, i to najvi{e prvih pet
dana. Nakon toga se smanjilo do 15% od po~etne vrijednosti. Koncentracije olova u krvi, me|utim, povisile su se 15
dana nakon zavr{etka tretmana, ali nisu prema{ile vrijednost od 40 µg/100 ml. Nakon ponovljenog testa mobilizacije
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EDTA-om, olovo u urinu iznosilo je 23–68% od one vrijednosti koja je dobivena prije primjene DMSA. Izlu~ivanje cinka
i bakra urinom bilo je za vrijeme postupka povi{eno 2–3 puta, a nije bilo promjena u izlu~ivanju ‘eljeza, kalcija i
magnezija.
Mo‘e se zaklju~iti da DMSA u~inkovito smanjuje koncentracije olova u radnika profesionalno izlo‘enih tom
toksi~nom metalu.
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bakar, CaNa2EDTA, cink, kalcij, krv, kelatiraju}a sredstva, magnezij, mobilizacijski test, urin, ‘eljezo
Requests for reprints:
Maja Blanu{a, Ph.D.
Institute for Medical Research and Occupational Health,
2 Ksaverska St., P.O. Box 291,
HR-10001 Zagreb, Croatia
E-mail: mblanusa@imi.hr
